HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Clinical value of MRD detection in blood cancers ‘increasingly difficult to ignore’
-
- 2013 Hematology Drugs in the Pipeline
- Ariad suspends Iclusig marketing, sales due to severe blood clotting
- Online chats allow patients, physicians and advocates to share insights, experiences William Wood, MD
- PFS may be surrogate endpoint in advanced RCC
- Most breast cancer deaths occurred in unscreened women
- Docetaxel, cisplatin, 5-FU regimen shows promise in anal carcinoma
- Sociodemographic factors contribute to underutilization of radiation in glioblastoma
- Oral S-1 with cisplatin, radiotherapy appears safe, effective in advanced NSCLC
-
- Cost outweighed benefit of PSA screening among older men
- Gene expression profiling-based signature can help predict prognosis in myelodysplastic syndrome
- Increased use of chemotherapy for gastric cancer has not extended OS
- Postoperative VTE rate may not be accurate hospital quality measure
- Single-fraction radiation rarely used for patients with advanced prostate cancer
- STAG2 mutation associated with low-risk bladder cancer
- Surgery for head and neck cancers increased VTE risk
- Zoledronic acid remains preferred treatment for newly diagnosed multiple myeloma
-
- Adjuvant gemcitabine extended OS after pancreatic cancer surgery
- American College of Surgeons constructs surgical risk calculator
- Cancer risk found higher in women exposed to low-dose ionizing radiation than men
- Cancer risk higher with Crohn’s disease, not ulcerative colitis
- Combination therapy plus WBRT effective in CNS lymphoma
- Common flavonoid nutraceuticals may be endocrine disruptors
- Daily iron supplementation improved cognitive, physical performance in children with anemia
- D-dimer levels may predict postoperative VTE
-
- Differentiated thyroid cancer tripled risk for cardiovascular mortality
- Erlotinib plus bevacizumab extended PFS, increased toxicity in advanced NSCLC
- Etirinotecan pegol active in platinum-resistant ovarian cancer
- Family history influenced concordant, discordant cancer risks
- Guideline recommends HER-2 testing for all invasive breast cancers
- Higher BMI associated with differential survival in NSCLC
- Incidence, survival of gastroesophageal cancer similar regardless of locale
- Ipilimumab appeared effective for pretreated, metastatic mucosal melanoma
-
- Marital status predicted outcome in various cancer types
- Minimum excision margins suggested for skin cancer
- Mutation status predicted response to panitumumab plus FOLFOX4
- Nodules detected on CT scan may predict lung malignancy
- Obesity, socioeconomic status in adolescence may influence gastrointestinal cancer risk
- Ofatumumab-based chemoimmunotherapy effective in CLL
- Onartuzumab plus erlotinib prolonged survival in MET-positive NSCLC
- Patient factors linked to increased radiation exposure during percutaneous coronary intervention
-
- Regimen produced durable response in indolent B-cell, mantle cell lymphomas
- Response-guided neoadjuvant chemotherapy prolonged DFS in early-stage breast cancer
- SBRT appears effective for patients with low-, intermediate-risk prostate cancer
- Screening strategy identified ovarian cancer early in postmenopausal women
- Single-agent lenalidomide safe, effective in mantle-cell lymphoma
- Single-agent quizartinib safe, effective in relapsed AML
- Stereotactic radiosurgery superior to WBRT in younger adults with brain metastases
- Study suggests association between HNSCC, dental caries
-
- Thrombotic thrombocytopenia purpura survivors may be at risk for poor health
- Treatment regimens differed for elderly, younger patients
- HSCT for beta-thalassemia improved long-term quality of life
- GSK: Immunotherapeutic did not meet co-primary endpoint in melanoma study
- Measure to fix physicians’ Medicare reimbursement formula now estimated to cost $175 billion
- Myriad Genetics announces effective study results for melanoma test
- SQUIRE: Necitumumab improved OS in stage IV NSCLC
- ASH appoints 3 to executive committee
-
- Cleveland Clinic fills two leadership posts
- Institution opens radiation center
- OSU center earns Magnet designation
- UT Southwestern names surgery chair
- Diabetes increased risk for breast, colorectal cancers
- Free screenings, education increased cancer awareness in urban areas
- Malignancy burden in aging HIV patients likely to increase
- Antibody-drug conjugate demonstrated activity against guanylyl cyclase C in pancreatic cancer
-
- Dinaciclib potential inhibitor of tumor growth in pancreatic cancer
- Genome project uncovers new drivers, molecular features in papillary thyroid cancer
- INSTIs appear best for HIV patients with cancer
- MIVAP may be effective alternative for hyperparathyroidism
- Next-generation sequencing tool shows 96% specificity in thyroid cancer detection
- PD-L1 inhibitor demonstrated activity in smokers with NSCLC
- RET, RAS mutations affected cabozantinib response in medullary thyroid cancer
- TERT promoter and BRAF mutation co-existence defines ‘most aggressive subgroup of PTC’
-
- Journals help patients maintain focus, explore feelings during life-changing illness Christine A. Zawistowski, MD